PEOPLE - Eragen makes appointment:
This article was originally published in Clinica
Molecular diagnostics firm Eragen (Madison, Wisconsin) has appointed Miguel Blanc as vice-president of corporate development. With more than ten years' experience in this specialist area, Mr Blanc joins the firm from GE Healthcare, where he was manager of global business development and played a role in several major acquisitions for the $3bn biosciences division during his tenure there. His list of achievements includes completing the strategic assessment and due diligence for GE's entry into the life sciences market through the $11bn-acquisition of Amersham in 2004, and being instrumental in the (ultimately aborted) $8.13bn acquisition of Abbott Labs' diagnostics and POC divisions.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.